• Transcode Therapeutics disclosed a Form 3 filing showing DEFJ, LLC as a 10% owner with 300,040 common shares.
• Filing also reports direct holdings of Series A Non-Voting Convertible Preferred Stock convertible into 11,813,859 common shares.
• Series B Non-Voting Convertible Preferred Stock was reported as convertible into 2,020,582 common shares.
• Event date was July 27, 2026; filing date was Aug. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091074), on August 05, 2026, and is solely responsible for the information contained therein.